Who this is for: GPs and medical officers who see undifferentiated cough and fever daily and need a clean pathway from suspicion to GeneXpert to the National TB Programme (NTP), without starting ad hoc regimens.

Epidemiology in Pakistan

Pakistan ranks fifth among high-burden countries, with an estimated incidence above 250 per 100,000 and over 600,000 new cases each year, alongside a significant load of rifampicin-resistant and MDR disease (roughly 4 percent of new cases). Around half of prevalent cases are never notified, and most patients first contact a private GP, which makes primary care the front line of case finding. Every district hosts NTP-linked diagnostic and DOTS treatment sites where diagnosis and drugs are free.

Who to suspect

Screen with the WHO four-symptom rule: cough (classically more than 2 weeks, but any duration in high-risk patients), fever, night sweats, weight loss. Add haemoptysis, contact with a TB patient, diabetes, HIV, malnutrition, and prior incomplete TB treatment as amplifiers. Extrapulmonary TB is common: painless cervical lymphadenopathy, pleural effusion, chronic back pain (Pott spine), sterile pyuria, ascites and lymphocytic meningitis all deserve the thought.

Differentials: post-viral cough, asthma and COPD, bronchiectasis, lung abscess, community-acquired pneumonia that fails to resolve, lung malignancy in smokers, and in children pertussis and foreign body. A pneumonia that has not cleared clinically and radiologically at 4 to 6 weeks is TB until excluded.

Diagnostic workup

  1. Xpert MTB/RIF Ultra (GeneXpert) on sputum is the WHO-recommended initial test, not smear microscopy, because it is more sensitive and reports rifampicin resistance in under 2 hours. NTP sites run it free; know your nearest machine.
  2. Two spot sputum samples suffice where Ultra is unavailable and smear microscopy is the fallback; a negative smear never excludes TB.
  3. Chest X-ray supports diagnosis and helps in smear-negative or Ultra-negative patients with high clinical suspicion; upper-zone infiltrates and cavitation are classic but any pattern occurs, especially with diabetes or HIV.
  4. Baseline where feasible: HIV testing (WHO-recommended for all TB patients), random glucose or HbA1c (diabetes doubles TB risk and worsens outcomes), LFTs and creatinine before therapy when available; do not delay treatment for missing baselines in a sick patient.
  5. For lymph node disease, fine needle aspiration for cytology plus Xpert on the aspirate is usually diagnostic and available in cities.

If Xpert reports rifampicin resistance, do not start first-line drugs; refer directly to the Programmatic Management of Drug-Resistant TB (PMDT) site for regimen design (all-oral bedaquiline-based regimens, including the 6-month BPaLM regimen endorsed by WHO in 2022).

Treatment: standard regimens, delivered through DOTS

Drug-susceptible pulmonary TB in adults: 2 months of HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol) followed by 4 months of HR, dosed by weight band with fixed-dose combinations supplied free by the NTP. Typical adult daily doses: isoniazid 5 mg per kg (max 300 mg), rifampicin 10 mg per kg (max 600 mg), pyrazinamide 25 mg per kg, ethambutol 15 mg per kg. Add pyridoxine 25 mg daily for pregnant women, diabetics, malnourished patients and those with HIV.

Children: weight-band paediatric FDCs; WHO 2022 guidance permits a 4-month regimen (2HRZE or 2HRZ plus 2HR) for non-severe TB in children aged 3 months to 16 years, decided at the treating DOTS centre.

The GP role is not to dispense private regimens but to register every patient with the NTP DOTS network, where treatment is observed, free and counted. Private prescriptions of partial regimens are a major driver of resistance in Pakistan. Counsel on the orange discolouration of urine (rifampicin), the need for daily dosing, and 5 to 7 days of hepatotoxicity symptoms to report (vomiting, jaundice, right upper quadrant pain).

Contact management: screen household contacts; give TB preventive therapy (TPT, such as 6 months of isoniazid or 3 months of weekly isoniazid-rifapentine where available) to under-5 contacts and HIV-positive contacts once active disease is excluded, per WHO consolidated TPT guidelines.

Red flags: refer or admit

  • Massive haemoptysis, respiratory distress, SpO2 below 90 percent.
  • Rifampicin resistance on Xpert, prior treatment failure, or relapse.
  • Jaundice or transaminases more than 3 times normal with symptoms on therapy (stop drugs, refer).
  • TB meningitis, pericarditis, spinal disease, and all paediatric severe disease.
  • Pregnancy with TB needs joint management but standard HRZE is safe; streptomycin is not.

Follow-up schedule

Sputum smear or Xpert review at the end of month 2, month 5 and month 6 per NTP protocol (done at the DOTS centre); the GP checks weight, adherence and side effects monthly and re-engages defaulters within days, not weeks. A missed dose caught early is a phone call; caught late it is relapse and resistance. The MyPatient EHR problem list keeps TB registration numbers and follow-up sputum dates visible at every visit, which is precisely the reminder infrastructure DOTS assumes. Share the patient guide to share to counter stigma and explain the free-treatment pathway.

Key points

  • Any cough over 2 weeks gets a TB screen; GeneXpert Ultra is the first test, not smear.
  • Rifampicin resistance on Xpert means PMDT referral, never empiric first-line drugs.
  • Standard regimen is 2HRZE/4HR by weight band, free through DOTS; register every case.
  • Screen contacts; give preventive therapy to under-5s and HIV-positive contacts.
  • Test all TB patients for HIV and diabetes.
  • Month 2, 5 and 6 sputum checks define cure; chase every missed dose immediately.

References

  • WHO Consolidated Guidelines on Tuberculosis, Module 3: Diagnosis - Rapid Diagnostics for TB Detection. World Health Organization, 2021 update.
  • WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Susceptible TB. World Health Organization, 2022.
  • WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant TB. World Health Organization, 2022.
  • WHO Consolidated Guidelines on Tuberculosis, Module 1: Prevention - TB Preventive Treatment. World Health Organization, 2020.
  • National TB Control Programme Pakistan: Technical Guidelines for TB Control. NTP, Ministry of National Health Services, 2019.

Clinical judgement and local protocols take precedence.